Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Andréas Mackensen, Fabian Müller, Dimitrios Mougiakakos, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2124-2132
Closed Access | Times Cited: 554

Showing 1-25 of 554 citing articles:

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 1, pp. 15-29
Open Access | Times Cited: 376
T cells in health and disease
Lina Sun, Yanhong Su, Anjun Jiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 355
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
Fabian Müller, Jule Taubmann, Laura Bucci, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 8, pp. 687-700
Closed Access | Times Cited: 306
CAR T therapy beyond cancer: the evolution of a living drug
Daniel Baker, Zoltàn Arany, Joseph A. Baur, et al.
Nature (2023) Vol. 619, Iss. 7971, pp. 707-715
Closed Access | Times Cited: 233
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
Mary K. Crow
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 8, pp. 999-1014
Closed Access | Times Cited: 182
From bench to bedside: the history and progress of CAR T cell therapy
Aroshi Mitra, Amrita Barua, Luping Huang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 181
CAR T-cell therapy in autoimmune diseases
Georg Schett, Andréas Mackensen, Dimitrios Mougiakakos
The Lancet (2023) Vol. 402, Iss. 10416, pp. 2034-2044
Closed Access | Times Cited: 162
CD19-targeted CAR T cells in refractory antisynthetase syndrome
Fabian Müller, Sebastian Boeltz, Johannes Knitza, et al.
The Lancet (2023) Vol. 401, Iss. 10379, pp. 815-818
Open Access | Times Cited: 147
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
Ann‐Christin Pecher, Luca Hensen, Reinhild Klein, et al.
JAMA (2023) Vol. 329, Iss. 24, pp. 2154-2154
Open Access | Times Cited: 116
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
Volkan Granit, Michael Benatar, Metin Kurtoğlu, et al.
The Lancet Neurology (2023) Vol. 22, Iss. 7, pp. 578-590
Closed Access | Times Cited: 115
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Brad H. Rovin, Isabelle Ayoub, Tak Mao Chan, et al.
Kidney International (2024) Vol. 105, Iss. 1, pp. S1-S69
Open Access | Times Cited: 110
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Connor A. Tsuchida, Nadav Brandes, Raymund Bueno, et al.
Cell (2023) Vol. 186, Iss. 21, pp. 4567-4582.e20
Open Access | Times Cited: 92
Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results
Chuan Qin, Dai‐Shi Tian, Luo‐Qi Zhou, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 82
Challenges and new technologies in adoptive cell therapy
Pengchao Zhang, Guizhong Zhang, Xiaochun Wan
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 81
mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications
Yu‐Shiuan Wang, Monika Kumari, Guanhong Chen, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 74
Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus
Daniele Accapezzato, Rosalba Caccavale, Maria Pia Paroli, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6578-6578
Open Access | Times Cited: 67
Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells
S. Momsen Reincke, Niels von Wardenburg, Marie A. Homeyer, et al.
Cell (2023) Vol. 186, Iss. 23, pp. 5084-5097.e18
Open Access | Times Cited: 67
CAR-T cell manufacturing: Major process parameters and next-generation strategies
Melanie Ayala Ceja, Mobina Khericha, Caitlin Harris, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 2
Open Access | Times Cited: 66
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System
Magdi Elsallab, Moataz Ellithi, Matthew A. Lunning, et al.
Blood (2024) Vol. 143, Iss. 20, pp. 2099-2105
Open Access | Times Cited: 66
CAR T Cell Therapy: A Versatile Living Drug
Rodrigo C. De Marco, Héctor J. Monzó, Päivi M. Ojala
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6300-6300
Open Access | Times Cited: 63
Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis
Wolfgang Merkt, Merle Freitag, Maren Claus, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 4, pp. 543-546
Open Access | Times Cited: 60
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
Xiaobing Wang, Xinyu Wu, Binghe Tan, et al.
Cell (2024) Vol. 187, Iss. 18, pp. 4890-4904.e9
Closed Access | Times Cited: 58
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions
Edward R. Scheffer Cliff, Amar H. Kelkar, David A. Russler‐Germain, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 54
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Felix Fischbach, Johanna Richter, Lena Kristina Pfeffer, et al.
Med (2024) Vol. 5, Iss. 6, pp. 550-558.e2
Open Access | Times Cited: 53
The role of inflammation in autoimmune disease: a therapeutic target
Yu Xiang, Mingxue Zhang, D.Y. Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top